Antibodies fused to innate immune molecules reduce initiation of Cryptosporidium parvum infection in mice

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 4, 2010, Pages 1385-1392

  Imboden, Michael ^a   Riggs, Michael W ^b   Schaefer, Deborah A ^b   Homan, E Jane ^a   Bremel, Robert D ^a  

^a IoGenetics LLC   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY BIOCIDE HYBRID PROTEIN; ANTIPROTOZOAL AGENT; BIOCIDE; CIMETIDINE; ENZYME; EPITOPE; HYBRID PROTEIN; PEPTIDE; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTESTINE EPITHELIUM; MAMMAL CELL; MEMBRANE DAMAGE; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE VIABILITY; PRIORITY JOURNAL; SPOROZOITE;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, PROTOZOAN; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; IMMUNITY, INNATE; MICE; MICE, INBRED ICR; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SPOROZOITES;

EID: 77950153280     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00754-09     Document Type: Article

References (39)

1. Aley, S. B., M. Zimmerman, M. Hetsko, M. E. Selsted, and F. D. Gillin. 1994. Killing of Giardia lamblia by cryptdins and cationic neutrophil peptides. Infect. Immun. 62:5397-5403.
2. Arrowood, M. J., and K. Donaldson. 1996. Improved purification methods for calf-derived Cryptosporidium parvum oocysts using discontinuous sucrose and cesium chloride gradients. J. Eukaryot. Microbiol. 43:89S.
3. Arrowood, M. J., J. M. Jaynes, and M. C. Healey. 1991. In vitro activities of lytic peptides against the sporozoites of Cryptosporidium parvum. Antimicrob. Agents Chemother. 35:224-227.
4. Baral, T. N., S. Magez, B. Stijlemans, K. Conrath, B. Vanhollebeke, E. Pays, S. Muyldermans, and P. De Baetselier. 2006. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat. Med. 12:580-584.
5. Bowdish, D. M., D. J. Davidson, Y. E. Lau, K. Lee, M. G. Scott, and R. E. Hancock. 2005. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77:451-459.
6. Cama, V. A., J. M. Ross, S. Crawford, V. Kawai, R. Chavez-Valdez, D. Vargas, A. Vivar, E. Ticona, M. Navincopa, J. Williamson, Y. Ortega, R. H. Gilman, C. Bern, and L. Xiao. 2007. Differences in clinical manifestations among Cryptosporidium species and subtypes in HIV-infected persons. J. Infect. Dis. 196:684-691.
7. Carryn, S., D. A. Schaefer, M. Imboden, E. J. Homan, R. D. Bremel, and M. W. Riggs. 2004. Phospholipases and cationic peptides neutralize Cryptosporidium parvum sporozoite infectivity by either parasiticidal or non-parasiticidal mechanisms. Int. J. Antimicrob. Agents 24(Suppl. 2):S117.
8. de Graaf, D. C., E. Vanopdenbosch, L. M. Ortega-Mora, H. Abbassi, and J. E. Peeters. 1999. A review of the importance of cryptosporidiosis in farm animals. Int. J. Parasitol. 29:1269-1287.
9. Dillingham, R., A. Lima, and R. Guerrant. 2002. Cryptosporidiosis: epidemiology and impact. Microbes Infect. 4:1059.
10. Fayer, R. 2008. General biology, p. 10-11. In R. Fayer and L. Xiao (ed.), Cryptosporidium and cryptosporidiosis, 2nd ed. CRC Press, Boca Raton, FL.
11. Giacometti, A., O. Cirioni, M. S. Del Prete, B. Skerlavaj, R. Circo, M. Zanetti, and G. Scalise. 2003. In vitro effect on Cryptosporidium parvum of short-term exposure to cathelicidin peptides. J. Antimicrob. Chemother. 51:843-847.
12. Heine, J., J. F. Pohlenz, H. W. Moon, and G. N. Woode. 1984. Enteric lesions and diarrhea in gnotobiotic calves monoinfected with Cryptosporidium species. J. Infect. Dis. 150:768-775.
13. Hong, D. K., C. J. Wong, and K. Gutierrez. 2007. Severe cryptosporidiosis in a seven-year-old renal transplant recipient: case report and review of the literature. Pediatr. Transplant. 11:94-100.
14. Huang, D. B., C. Chappell, and P. C. Okhuysen. 2004. Cryptosporidiosis in children. Semin. Pediatr. Infect. Dis. 15:253-259.
15. Institute of Laboratory Animal Resources. 1985. Guide for the care and use of laboratory animals. Public Health Service, Bethesda, MD.
16. Johansson, J., G. H. Gudmundsson, M. E. Rottenberg, K. D. Berndt, and B. Agerberth. 1998. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol. Chem. 273:3718-3724.
17. McGwire, B. S., C. L. Olson, B. F. Tack, and D. M. Engman. 2003. Killing of African trypanosomes by antimicrobial peptides. J. Infect. Dis. 188:146-152.
18. Okhuysen, P. C., and A. C. White, Jr. 1999. Parasitic infections of the intestines. Curr. Opin. Infect. Dis. 12:467-472.
19. Peschen, D., H. P. Li, R. Fischer, F. Kreuzaler, and Y. C. Liao. 2004. Fusion proteins comprising a Fusarium-specific antibody linked to antifungal peptides protect plants against a fungal pathogen. Nat. Biotechnol. 22:732-738.
20. Riggs, M. W., D. A. Schaefer, and S. Carryn. 2004. Control of bovine cryptosporidiosis using antibody-based strategies to disrupt parasite ligand function and target delivery of parasiticidal agents, p. 162. In Proceedings of the 85th Conference of Research Workers in Animal Diseases. Conference of Research Workers in Animal Diseases, Fort Collins, CO.
21. Riggs, M. W., V. A. Cama, H. L. Leary, Jr., and C. R. Sterling. 1994. Bovine antibody against Cryptosporidium parvum elicits a circumsporozoite precipitate-like reaction and has immunotherapeutic effect against persistent cryptosporidiosis in SCID mice. Infect. Immun. 62:1927-1939.
22. Riggs, M. W., T. C. McGuire, P. H. Mason, and L. E. Perryman. 1989. Neutralization-sensitive epitopes are exposed on the surface of infectious Cryptosporidium parvum sporozoites. J. Immunol. 143:1340-1345.
23. Riggs, M. W., M. R. McNeil, L. E. Perryman, A. L. Stone, M. S. Scherman, and R. M. O'Connor. 1999. Cryptosporidium parvum sporozoite pellicle antigen recognized by a neutralizing monoclonal antibody is a beta-mannosylated glycolipid. Infect. Immun. 67:1317-1322.
24. Riggs, M. W., and L. E. Perryman. 1987. Infectivity and neutralization of Cryptosporidium parvum sporozoites. Infect. Immun. 55:2081-2087.
25. Riggs, M. W., A. L. Stone, P. A. Yount, R. C. Langer, M. J. Arrowood, and D. L. Bentley. 1997. Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites. J. Immunol. 158:1787-1795.
26. Schaefer, D. A., B. A. Auerbach-Dixon, and M. W. Riggs. 2000. Characterization and formulation of multiple epitope-specific neutralizing monoclonal antibodies for passive immunization against cryptosporidiosis. Infect. Immun. 68:2608-2616.
27. Schnyder, M., L. Kohler, A. Hemphill, and P. Deplazes. 2009. Prophylactic and therapeutic efficacy of nitazoxanide against Cryptosporidium parvum in experimentally challenged neonatal calves. Vet. Parasitol. 160:149-154.
28. Sørensen, O., K. Arnljots, J. B. Cowland, D. F. Bainton, and N. Borregaard. 1997. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 90:2796-2803.
29. Stockdale, H. D., J. A. Spencer, and B. L. Blagburn. 2008. Prophylaxis and chemotherapy, p. 28-35. In R. Fayer and L. Xiao (ed.), Cryptosporidium and cryptosporidiosis, 2nd ed. CRC Press, Boca Raton, FL.
30. Sulzyc-Bielicka, V., W. Kuzna-Grygiel, L. Kolodziejczyk, D. Bielicki, J. Kladny, M. Stepien-Korzonek, and B. Telatynska-Smieszek. 2007. Cryptosporidiosis in patients with colorectal cancer. J. Parasitol. 93:722-724.
31. Tanaka, T., Y. Omata, A. Saito, K. Shimazaki, K. Yamauchi, M. Takase, K. Kawase, K. Igarashi, and N. Suzuki. 1995. Toxoplasma gondii: parasiticidal effects of bovine lactoferricin against parasites. Exp. Parasitol. 81:614-617.
32. Tarver, A. P., D. P. Clark, G. Diamond, J. P. Russell, H. Erdjument-Bromage, P. Tempst, K. S. Cohen, D. E. Jones, R. W. Sweeney, M. Wines, S. Hwang, and C. L. Bevins. 1998. Enteric beta-defensin: molecular cloning and characterization of a gene with inducible intestinal epithelial cell expression associated with Cryptosporidium parvum infection. Infect. Immun. 66:1045-1056.
33. Tzipori, S., and G. Widmer. 2008. A hundred-year retrospective on cryptosporidiosis. Trends Parasitol. 24:184-189.
34. Wiersma, E. J., and M. J. Shulman. 1995. Assembly of IgM. Role of disulfide bonding and noncovalent interactions. J. Immunol. 154:5265- 5272.
35. Xiao, L., and U. M. Ryan. 2004. Cryptosporidiosis: an update in molecular epidemiology. Curr. Opin. Infect. Dis. 17:483-490.
36. Zaalouk, T. K., M. Bajaj-Elliott, J. T. George, and V. McDonald. 2004. Differential regulation of beta-defensin gene expression during Cryptosporidium parvum infection. Infect. Immun. 72:2772-2779.
37. Zhu, G. 2008. Biochemistry, p. 69-71. In R. Fayer and L. Xiao (ed.), Cryptosporidium and cryptosporidiosis, 2nd ed. CRC Press, Boca Raton, FL.
38. Ziegler, H. K., and C. A. Orlin. 1984. Analysis of Listeria monocytogenes antigens with monoclonal antibodies. Clin. Invest. Med. 7:239-242.
39. Zufferey, R., J. E. Donello, D. Trono, and T. J. Hope. 1999. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73:2886-2892.